MD Anderson Cancer Center spinout OncoResponse has added $40.6m to its coffers thanks to series C investors including Arch Venture Partners.
OncoResponse, a US-based immunotherapy spinout of University of Texas MD Anderson Cancer Center, picked up $40.6m in a series C round today led by members of asset manager Magnetar Group.
Arch Venture Partners, Yonjin Venture, Bering Capital, RiverVest Venture Partners, Qatar Investment Authority (QIA), Redmile Group, Canaan Partners and 3B Future Health Fund (Helsinn Investment Fund), a vehicle for cancer drug developer Helsinn Group.
OncoResponse is developing antibodies intended to harness the body’s immune system to combat specific…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
